Small Molecule CDMO Market Size, Share & Trends Analysis Report By Product (APIs, Finished Drug Products), By Drug Type (Generics, Innovators), By Application (Oncology, CVD, CNS Conditions, Autoimmune, Others), By Region, And Segment Forecasts, 2025 - 20
Description
Small Molecule CDMO Market Summary
The global small molecule CDMO market was estimated at USD 71.3 billion in 2024 and is projected to reach USD 126.2 billion by 2033, growing at a CAGR of 6.7% from 2025 to 2033. The growth of the market is due to a convergence of strategic outsourcing trends, robust pharmaceutical pipelines, and global manufacturing shifts.
Pharmaceutical and biotech companies increasingly rely on CDMOs to streamline R&D costs, accelerate time-to-market, and access specialized capabilities, particularly for highly potent APIs and complex chemistries. The consistent approval of small molecule drugs, especially in therapeutic areas such as oncology, infectious diseases, and cardiology, sustains strong demand for both clinical and commercial-scale manufacturing.
The market is driven by the evolving nature of pharmaceutical innovation and the changing economic landscape of drug development. The emergence of biotech firms and virtual pharma companies, which often lack in-house infrastructure for R&D, scale up, or GMP manufacturing, is driving the market growth. These companies are turning to CDMOs not just as suppliers but as strategic collaborators to bring their molecules to market quickly and compliantly. Unlike in the past where outsourcing was cost-driven, today’s engagements are increasingly innovation-driven-relying on CDMOs for specialized process chemistry, formulation science, and regulatory knowledge. This shift is particularly evident in the development of high-value small molecules such as antibody-drug conjugates (ADCs), HPAPIs, and targeted oncology drugs, where manufacturing complexity and containment needs are high.
Moreover, the growing trend towards digitalization and advanced manufacturing technologies within the CDMO ecosystem is also contributing to market growth.AI-driven predictive modeling, continuous flow processing, and real-time release testing (RTRT) are transforming the cost-efficiency and flexibility of small molecule production. These innovations allow CDMOs to differentiate their offerings, improve batch yields, and meet quality requirements in a faster, more data-rich environment. In addition, large pharmaceutical companies are seeking sustainability in their supply chains, and CDMOs with green chemistry capabilities or low-carbon production practices are becoming more attractive partners. The market is also benefiting from regional shifts in supply chain strategy due to geopolitical instability and drug shortages-prompting Western pharma firms to diversify their supplier base and seek CDMOs in North America and Europe with redundant capacity.
Global Small Molecule CDMO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule CDMO market report based on product, drug type, application, and region:
The global small molecule CDMO market was estimated at USD 71.3 billion in 2024 and is projected to reach USD 126.2 billion by 2033, growing at a CAGR of 6.7% from 2025 to 2033. The growth of the market is due to a convergence of strategic outsourcing trends, robust pharmaceutical pipelines, and global manufacturing shifts.
Pharmaceutical and biotech companies increasingly rely on CDMOs to streamline R&D costs, accelerate time-to-market, and access specialized capabilities, particularly for highly potent APIs and complex chemistries. The consistent approval of small molecule drugs, especially in therapeutic areas such as oncology, infectious diseases, and cardiology, sustains strong demand for both clinical and commercial-scale manufacturing.
The market is driven by the evolving nature of pharmaceutical innovation and the changing economic landscape of drug development. The emergence of biotech firms and virtual pharma companies, which often lack in-house infrastructure for R&D, scale up, or GMP manufacturing, is driving the market growth. These companies are turning to CDMOs not just as suppliers but as strategic collaborators to bring their molecules to market quickly and compliantly. Unlike in the past where outsourcing was cost-driven, today’s engagements are increasingly innovation-driven-relying on CDMOs for specialized process chemistry, formulation science, and regulatory knowledge. This shift is particularly evident in the development of high-value small molecules such as antibody-drug conjugates (ADCs), HPAPIs, and targeted oncology drugs, where manufacturing complexity and containment needs are high.
Moreover, the growing trend towards digitalization and advanced manufacturing technologies within the CDMO ecosystem is also contributing to market growth.AI-driven predictive modeling, continuous flow processing, and real-time release testing (RTRT) are transforming the cost-efficiency and flexibility of small molecule production. These innovations allow CDMOs to differentiate their offerings, improve batch yields, and meet quality requirements in a faster, more data-rich environment. In addition, large pharmaceutical companies are seeking sustainability in their supply chains, and CDMOs with green chemistry capabilities or low-carbon production practices are becoming more attractive partners. The market is also benefiting from regional shifts in supply chain strategy due to geopolitical instability and drug shortages-prompting Western pharma firms to diversify their supplier base and seek CDMOs in North America and Europe with redundant capacity.
Global Small Molecule CDMO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule CDMO market report based on product, drug type, application, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Active Pharmaceutical Ingredients (API)
- Finished Drug Products
- Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
- Innovators
- Generics
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Oncology
- Cardiovascular Disease
- Central Nervous System (CNS) Conditions
- Autoimmune/Inflammation
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
145 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Small Molecule CDMO Market: Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Small Molecule CDMO Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Technological Landscape
- 3.4. Pricing Model Analysis
- 3.5. Clinical Trials Volume Analysis
- 3.6. Small Molecule CDMO Market: Analysis Tools
- 3.6.1. Porter’s Five Forces Analysis
- 3.6.2. PESTEL by SWOT Analysis
- Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Small Molecule CDMO Market Product Movement Analysis
- 4.3. Global Small Molecule CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Active Pharmaceutical Ingredients (API)
- 4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
- 4.5. Finished Drug Products
- 4.5.1. Finished Drug Products Market Estimates and Forecasts, 2021 - 2033 (USD million)
- Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Small Molecule CDMO Market Drug Type Movement Analysis
- 5.3. Global Small Molecule CDMO Market Size & Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
- 5.4. Innovators
- 5.4.1. Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Generics
- 5.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Small Molecule CDMO Market Application Movement Analysis
- 6.3. Global Small Molecule CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Oncology
- 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Cardiovascular Disease
- 6.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Central Nervous System (CNS) Conditions
- 6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Autoimmune/Inflammation
- 6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. Others
- 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis by Product, Drug Type, Application
- 7.1. Regional Market Dashboard
- 7.2. Global Regional Market Snapshot
- 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competitive Scenario
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. MEA
- 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
- 8.2. Small Molecule CDMO Market Share/Assessment Analysis, 2024
- 8.3. Company Profiles
- 8.3.1. Lonza
- 8.3.1.1. Company overview
- 8.3.1.2. Financial performance
- 8.3.1.3. Service benchmarking
- 8.3.1.4. Strategic initiatives
- 8.3.2. Catalent, Inc.
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Service benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. Thermo Fisher Scientific Inc.
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Service benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. Cambrex Corporation
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Service benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Bellen Chemistry
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Service benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Siegfried Holding AG
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Service benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Recipharm AB
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Service benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Eurofins Scientific
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Service benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Aurigene Pharmaceutical Services Ltd
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Service benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. CordenPharma International
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Service benchmarking
- 8.3.10.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
